Côd QR

Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis

Abstract Background In 2014 and 2015, biosimilars for the drugs filgrastim, infliximab, and insulin glargine were approved for use in Canada. The introduction of biosimilars in Canada could provide significant cost savings for the Canadian healthcare system over originator biologic drugs, however it...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Kerry Mansell, Hishaam Bhimji, Dean Eurich, Holly Mansell
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMC 2019-11-01
Cyfres:BMC Health Services Research
Pynciau:
Biosimilars
Cost-savings
Filgrastim
Infliximab
Insulin glargine
Mynediad Ar-lein:http://link.springer.com/article/10.1186/s12913-019-4680-2
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg